Clinical Trial Detail

NCT ID NCT03318939
Title Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Spectrum Pharmaceuticals, Inc
Indications

lung non-small cell carcinoma

Therapies

Poziotinib

Age Groups: adult senior

Additional content available in CKB BOOST